Cencora에 대한 매도 수량은 투자자에게 Cencora의 주식 하락에 베팅하는 정도를 알려줍니다. 매도 수량 데이터는 2주마다 업데이트됩니다.

Cencora (NYSE:COR) 주식, 공매도 수량 보고

Cencora

Cencora is one of three domestic leading pharmaceutical wholesalers. It sources and distributes branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospital networks, and healthcare providers. It and McKesson and Cardinal Health constitute over 90% of the us pharmaceutical wholesale industry. Cencora also provides commercialization services for manufacturers of pharmaceuticals and medical devices, global specialty drug logistics (World Courier), and animal health product distribution (MWI Animal Health). Cencora expanded its international presence in 2021 by purchasing Alliance Healthcare, one of the leading drug wholesalers in Europe.

CoreSite Realty

Large Cap

News

Movers

Trading Ideas

ASND

BMRN

BNTX

CHWY

KSPI

MUSA

RIVN

SMMT

이들 10개 대형주는 지난주 최악의 성과를 거두었다. 그것들이 당신의 포트폴리오에 있나요? 1. 서밋 테라퓨틱스(NASDAQ:SMMT)의 주식이 23.61% 하락했다. 이 회사는 새롭고 잠재적인 최초의 연구용 이중특이성 항체인 아이보네스시맙(ivonescimab)에 대한 데이터가 2024년 ESMO 연례 회의에서 발표되었다고 발표했다.

노보 노디스크, 츄이 및 페덱스는 지난주 최악의 성과를 보인 10개 대형주 중 일부 (9월 15일-9월 21일)

Equities

BEKE

BGNE

LULU

MSTR

NDSN

지난주 이들 10개 대형주는 최악의 성과를 거두었다. 그것들이 당신의 포트폴리오에 있나요? 내셔널 그리드 트랜스코(NYSE:NGG)가 70억 파운드의 자본금을 늘리고 연간 매출 결과가 전년 대비 감소했다고 보고한 후 주각가 17.1% 급락했다. 

지난주 최악의 성과를 보인 룰루레몬 애틀라티카 포함 10개의 대형주 (5월 19일-5월 26일)

Cencora Inc

Coreto

GLOBAL CORD BLOOD CORP by Global Cord Blood Corporation

Global Cord Blood Corp

CORNWALL RESOURCES INC by Cornwall Resources, Inc.

cVault.finance

Cordia Corp

CorEnergy Infrastructure Trust Inc Depositary Shares each representing 1/100th of a whole share of Series A Preferred Stock

Teucrium Corn Fund ETV

Coro Global Inc.

Pimco Investment Grade Corporate Bond Index Exchange-Traded Fund

IS GLBL CORP BND UCITS USD DIST ETF

UBS MSCI GLO LIQ ETF

CorEnergy Infrastructure Trust Inc OM

CorEnergy Infrastructure Trust Inc

Corcept Therapeutics Incorporated - Common Stock

Corcept Therapeutics Inc

UBS (CMCI CORN) USD ETF

Core Scientific Inc

Core Scientific Inc Ordinary Shares - Class A

Core Scientific, Inc. - Tranche 1 Warrants

Core Scientific, Inc. - Tranche 2 Warrants

Cencora (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COR#NYSE">COR</a>) has outperformed the market over the past 5 years by 9.08% on an annualized basis producing an average annual return of 23.07%. Currently, Cencora has a market capitalization of $44.71 billion. 
Buying $1000 In COR: If an investor had bought $1000 of COR stock 5 years ago, it would be worth $2,786.77 today based on a price of $228.11 for COR at the time of writing.
<h3>Cencora's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1727112615_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much $1000 Invested In Cencora 5 Years Ago Would Be Worth Today

These ten large-cap stocks were the worst performers in the last week. Are they in your portfolio?
<ol>
<li>Summit Therapeutics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMMT#NASDAQ">SMMT</a>) stock declined 23.61%. The company announced that data for the novel, potential first-in-class investigational bispecific antibody, ivonescimab, was presented <a href="https://www.benzinga.com//node/40873837" target="_blank" rel="noreferrer noopener">at the 2024 ESMO Annual Meeting</a>.</li>
<li>Joint Stock Company Kaspi.kz (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KSPI#NASDAQ">KSPI</a>) stock tumbled 21.66% after Culper Research <a href="https://www.benzinga.com//node/40943334" target="_blank" rel="noreferrer noopener">issued a short report on the company</a>.</li>
<li>BioMarin Pharmaceutical Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BMRN#NASDAQ">BMRN</a>) stock lost 16.74% last week <a href="https://www.benzinga.com//node/40885653" target="_blank" rel="noreferrer noopener">following strong dwarfism drug data</a> from rival Ascendis Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASND#NASDAQ">ASND</a>).</li>
<li>Rivian Automotive, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RIVN#NASDAQ">RIVN</a>) lost 13.26% <a href="https://www.benzinga.com//node/40961732" target="_blank" rel="noreferrer noopener">last week</a>.</li>
<li>FedEx Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FDX#NYSE">FDX</a>) stock fell 11.08% after the company reported worse-than-expected Q1 financial results and <a href="https://www.benzinga.com//node/40948046" target="_blank" rel="noreferrer noopener">cut FY25 guidance</a>.</li>
<li>BioNTech SE (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNTX#NASDAQ">BNTX</a>) stock decreased 9.01%. Pfizer, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>) and BioNTech received positive CHMP opinion for omicron KP.2-adapted <a href="https://www.benzinga.com//node/40956192" target="_blank" rel="noreferrer noopener">COVID-19 vaccine in the European Union</a>.</li>
<li>Arthur J. Gallagher &amp; Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AJG#NYSE">AJG</a>) stock fell 7.17%. Several analysts raised <a href="https://www.benzinga.com/quote/ajg/analyst-ratings" target="_blank" rel="noreferrer noopener">the price target on the stock</a>.</li>
<li>Chewy, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CHWY#NYSE">CHWY</a>) shares declined 6.97% after the company announced a selling stockholder&#8217;s public offering of shares <a href="https://www.benzinga.com//node/40949015" target="_blank" rel="noreferrer noopener">and a concurrent share repurchase</a>.</li>
<li>Novo Nordisk A/S (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) stock fell 6.93% after <a href="https://www.benzinga.com//node/40961934" target="_blank" rel="noreferrer noopener">headline results from the mid-stage study</a> of monlunabant in obese patients.</li>
<li>Murphy USA Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MUSA#NYSE">MUSA</a>) shares fell 6.90% after JP Morgan downgraded the stock from Neutral to Underweight but raised its <a href="https://www.benzinga.com/quote/musa/analyst-ratings" target="_blank" rel="noreferrer noopener">price target from $415 to $435</a>.</li>
</ol>
Also Read:
<ul>
<li><a href="https://www.benzinga.com/news/large-cap/24/09/40972008/constellation-energy-li-auto-and-carvana-are-among-top-11-large-cap-gainers-last-week-sept-16-sept" target="_blank" rel="noreferrer noopener">Constellation Energy, Li Auto And Carvana Are Among Top 11 Large Cap Gainers Last Week (Sept 16-Sept 20): Are The Others In Your Portfolio?</a></li>
</ul>
Photo via Shutterstock

Novo Nordisk, Chewy And FedEx Are Among Top 10 Large Cap Losers Last Week (Sept 15-Sept 21): Are The Others In Your Portfolio?

B of A Securities analyst Michael Funk downgrades Cencora (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COR#NYSE">COR</a>) from Buy to Neutral and lowers the price target from $275 to $245.

Downgrades

Price Target

Analyst Ratings

B of A Securities Downgrades Cencora to Neutral, Lowers Price Target to $245

Cencora (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COR#NYSE">COR</a>) has outperformed the market over the past 5 years by 10.52% on an annualized basis producing an average annual return of 23.18%. Currently, Cencora has a market capitalization of $46.36 billion. 
Buying $100 In COR: If an investor had bought $100 of COR stock 5 years ago, it would be worth $279.45 today based on a price of $236.53 for COR at the time of writing.
<h3>Cencora's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1725913814_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much You Would Have Made Owning Cencora Stock In The Last 5 Years

Cencora (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COR#NYSE">COR</a>) underwent analysis by 6 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">5</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $277.67, a high estimate of $287.00, and a low estimate of $249.00. This current average has increased by 1.4% from the previous average price target of $273.83. 
<img src="https://www.benzinga.com/files/images/story/2024/1725627654_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive Cencora. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>David Rodgers</td>
<td>Baird</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$283.00</td>
<td>$287.00</td>
</tr>
<tr>
<td>Lisa Gill</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$287.00</td>
<td>$280.00</td>
</tr>
<tr>
<td>Stephen Baxter</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$249.00</td>
<td>$236.00</td>
</tr>
<tr>
<td>David Rodgers</td>
<td>Baird</td>
<td>Raises</td>
<td>Outperform</td>
<td>$287.00</td>
<td>$285.00</td>
</tr>
<tr>
<td>David Rodgers</td>
<td>Baird</td>
<td>Raises</td>
<td>Outperform</td>
<td>$285.00</td>
<td>$280.00</td>
</tr>
<tr>
<td>Michael Cherny</td>
<td>Leerink Partners</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$275.00</td>
<td>$275.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Cencora. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Cencora compared to the broader market.</li>
<li>Price Targets: Analysts provide insights into price targets, offering estimates for the future value of Cencora's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Cencora's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/COR/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Cencora analyst ratings.</a>
<h2>Delving into Cencora's Background</h2>
Cencora is one of three domestic leading pharmaceutical wholesalers. It sources and distributes branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospital networks, and healthcare providers. It and McKesson and Cardinal Health constitute over 90% of the us pharmaceutical wholesale industry. Cencora also provides commercialization services for manufacturers of pharmaceuticals and medical devices, global specialty drug logistics (World Courier), and animal health product distribution (MWI Animal Health). Cencora expanded its international presence in 2021 by purchasing Alliance Healthcare, one of the leading drug wholesalers in Europe.
<h3>Cencora's Financial Performance</h3>
Market Capitalization: Surpassing industry standards, the company's market capitalization asserts its dominance in terms of size, suggesting a robust market position.
Positive Revenue Trend: Examining Cencora's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 10.9% as of 30 June, 2024, showcasing a substantial increase in top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Health Care sector.
Net Margin: Cencora's net margin excels beyond industry benchmarks, reaching 0.65%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): Cencora's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of 48.15%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): Cencora's ROA excels beyond industry benchmarks, reaching 0.74%. This signifies efficient management of assets and strong financial health.
Debt Management: Cencora's debt-to-equity ratio is notably higher than the industry average. With a ratio of 5.11, the company relies more heavily on borrowed funds, indicating a higher level of financial risk.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Deep Dive Into Cencora Stock: Analyst Perspectives (6 Ratings)

Baird analyst David Rodgers maintains Cencora (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COR#NYSE">COR</a>) with a Outperform and lowers the price target from $287 to $283.

Baird Maintains Outperform on Cencora, Lowers Price Target to $283

The three largest U.S. drug distributors have reached a settlement of $300 million to resolve claims from health insurers and benefit plans over their alleged role in fueling the opioid epidemic, according to court documents filed on Friday.
The settlement involves McKesson Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MCK#NYSE">MCK</a>), Cencora Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COR#NYSE">COR</a>), and Cardinal Health Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAH#NYSE">CAH</a>). The proposed class action settlement, disclosed in a federal court in Cleveland, Ohio, requires a judge&#8217;s approval.
Also Read: <a target="_blank" href="https://www.benzinga.com/news/large-cap/24/06/39546645/unitedhealths-optumrx-settles-opioid-prescription-claims-for-20m" rel="noreferrer noopener">UnitedHealth&#8217;s OptumRx Settles Opioid Prescription Claims for $20M</a>.
Reuters highlights that the settlement comes on the heels of a $21 billion agreement by the same companies to settle claims from state and local governments.
Those claims accused the distributors of failing to implement proper controls, which allowed large quantities of addictive painkillers to be diverted into illegal markets.
The new settlement addresses the claims of third-party payers, such as union funds, who bore the financial burden of overprescribed and overmarketed opioid medications and the subsequent treatment of opioid use disorder.
The distributors did not admit any wrongdoing as part of the settlement. The $300 million payment will be divided among the companies, with McKesson paying 38.1%, Cardinal Health and Cencora paying 30.9% and 31%, respectively.
The case is part of a broader wave of litigation against drug manufacturers, distributors, and pharmacies, seeking accountability for a nationwide opioid crisis that has claimed hundreds of thousands of lives over the past two decades.
These lawsuits have collectively resulted in over $50 billion in settlements, primarily with state and local governments.
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/24/09/40691948/praxis-precision-medicines-touts-encouraging-data-for-mid-stage-epilepsy-drug" target="_blank" rel="noreferrer noopener">Praxis Precision Medicines Touts Encouraging Data For Mid-Stage Epilepsy Drug</a>.</li>
</ul>
Image via Shutterstock

Health Care

Legal

General

Opioid Settlement: Drug Distributors McKesson, Cencora, Cardinal Health To Pay $300M To Health Insurers

Cencora (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COR#NYSE">COR</a>) has outperformed the market over the past 5 years by 8.99% on an annualized basis producing an average annual return of 22.95%. Currently, Cencora has a market capitalization of $46.29 billion. 
Buying $1000 In COR: If an investor had bought $1000 of COR stock 5 years ago, it would be worth $2,810.09 today based on a price of $236.16 for COR at the time of writing.
<h3>Cencora's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1724875245_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$1000 Invested In Cencora 5 Years Ago Would Be Worth This Much Today

Rumors

Watching Cencora; Traders Circulate Unconfirmed Analyst Comments Suggesting The Co Has Lost Its Partnership With Cigna To Distribute Branded Humira; Cigna To Transition Distribution Through Its Specialty Distributor Curascript Starting January 2025

Cardinal Health Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/cah#NYSE">CAH</a>) is a global pharmaceutical and medical products distributor serving over 100,000 hospitals. It&#39;s also the largest distributor of medical supplies and surgical products in the United States. Cardinal Health provides medical supplies and specialty therapeutics to 90% of the hospitals in the United States, as well as 60,000 pharmacies and over 10,000 specialty physician offices.
The rising trend in acute care utilization from emergency rooms, ambulatory and surgical care centers, and inpatient hospital visits has helped drive record results for the company. The stock is also a dividend aristocrat, having raised its dividend for nearly 40 consecutive years.
Cardinal Health operates in the medical sector with major healthcare services companies like McKesson Co. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/mck#NYSE">MCK</a>), Stryker Co. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/syk#NYSE">SYK</a>), and Cencora Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/cor#NYSE">COR</a>).
<h2>Cardinal Health&#39;s Massive Portfolio and Reach </h2>
The company&#39;s professional products range from durable medical equipment to anesthesia supplies, personal protective equipment (PPE), lab supplies, and surgical equipment. It carries over 46,000 home healthcare products to over 3.4 million patients. Its digital ecosystem supports medication adherence to over 23 million patients and over 60 payers. The company offers numerous tailored services, including data and analytics, to improve cost efficiencies, workflows, and waste reduction for ambulatory surgery centers, hospitals, pharmacies, and labs. They even provide customer packaging solutions to pharmaceuticals through its 60,000-square-foot facility with automated and semi-automated equipment accommodating small and large-volume batches and projects in compliance with all FDA standards.
<h2>Cardinal Health: Expanding Its Specialty Business </h2>
Cardinal continues to expand its specialty business, which focuses on distributing and servicing specialty pharmaceuticals, pharmacies, and physician practices. It offers technology platforms that help manage inventory, track patient outcomes, manage reimbursement cycles, and improve efficiency for pharmacies and practices. Specialty therapeutics include a wide array of high-cost, complex medications that often require special storage, handling, and patient support programs. In January 2024, the company agreed to acquire Specialty Networks for $1.2 billion in cash to accelerate growth in its Specialty business. &nbsp;
<img alt="Cardinal Health CAH stock chart" class="aligncenter" src="https://www.marketbeat.com/logos/articles/med_20240818185626_chartb-cah.jpg" style="height:750px; width:915px" />
<h2>CAH Stocks Forms a Cup and Handle Breakout Pattern </h2>
The daily candlestick chart for CAH illustrates a cup and handle breakout pattern. The cup lip line at $105.08 was tested on Aug. 8, 2024. The pullback formed the handle staging the rally into its earnings release. CAH gapped to the cup lip line and proceeded to break out higher after testing the support for two days. The daily relative strength index (RSI) has bounced to the 75-band. Pullback support levels are at $105.08, $102.81, $98.79, and $96.05.
<h2>Cardinal Health Beats Top and Bottom Line Estimates </h2>
The fiscal fourth-quarter 2024 earnings report indicated strong top- and bottom-line acceleration. Cardinal Health reported EPS of $1.84, which beat the consensus analyst estimates for $1.74 by 10 cents. Its non-GAAP operating earnings rose 14% to $605 million. Segment profit increases in the Global Medical Products and Distribution and Pharmaceuticals and Specialty Solutions segments primarily drove the growth. Revenues grew 12.1% YoY to $59.87 billion, which also beat the consensus analyst estimate of $58.74 billion.
Fiscal 2024 operating cash flow and adjusted free cash flow reached all-time highs of $3.8 billion and $3.9 billion, respectively. Fiscal full-year 2024 revenues rose 11% YoY to $226.8 billion. Full-year non-GAAP diluted EPS rose 29% to $7.53.
<h2>Cardinal Health Raises Its Guidance </h2>
The company issued upside fiscal full-year 2025 non-GAAP EPS of $7.55 to $7.70 versus $7.53 consensus estimates, raising it from previous guidance of $7.50. Full-year revenue is expected to grow 10% to 12% YoY. Its Pharmaceutical and Specialty Solutions segment is expected to see revenues decline 4% to 6% YoY. Its Global Medical Products and Distribution (GMPD) segment is expected to see 3% to 5% revenue growth. Other revenue is expected to grow 10% to 12% YoY.
Cardinal Health CEO Jason Hollar commented, &quot;We delivered robust cash flow generation, continued profit growth in the Pharmaceutical and Specialty Solutions segment and significant improvement driven by our GMPD Improvement Plan. We enter the new fiscal year with momentum and confidence, evidenced by our raised fiscal year 2025 guidance.&quot;
CAH analyst ratings and price targets are at MarketBeat. There are 12 analyst ratings on CAH stock, comprised of seven Buys, two Holds, and one Sell. Consensus analyst price targets point to a 7% upside at $117.45.
The article &quot;<a href="https://www.nasdaq.com/articles/cardinal-health-soars-americas-leading-acute-care-supplier">Cardinal Health Soars as America&#39;s Leading Acute Care Supplier</a>&quot; first appeared on MarketBeat.

Earnings

Guidance

Dividends

Markets

Cardinal Health Soars as America's Leading Acute Care Supplier

Ratings for Cencora (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COR#NYSE">COR</a>) were provided by 5 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Analysts have recently evaluated Cencora and provided 12-month price targets. The average target is $276.6, accompanied by a high estimate of $287.00 and a low estimate of $249.00. Observing a 1.99% increase, the current average has risen from the previous average price target of $271.20. 
<img src="https://www.benzinga.com/files/images/story/2024/1724252424_0.png" alt="price target chart" />
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
The standing of Cencora among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lisa Gill</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$287.00</td>
<td>$280.00</td>
</tr>
<tr>
<td>Stephen Baxter</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$249.00</td>
<td>$236.00</td>
</tr>
<tr>
<td>David Rodgers</td>
<td>Baird</td>
<td>Raises</td>
<td>Outperform</td>
<td>$287.00</td>
<td>$285.00</td>
</tr>
<tr>
<td>David Rodgers</td>
<td>Baird</td>
<td>Raises</td>
<td>Outperform</td>
<td>$285.00</td>
<td>$280.00</td>
</tr>
<tr>
<td>Michael Cherny</td>
<td>Leerink Partners</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$275.00</td>
<td>$275.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Cencora. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Cencora compared to the broader market.</li>
<li>Price Targets: Delving into movements, analysts provide estimates for the future value of Cencora's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Cencora's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/COR/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Cencora analyst ratings.</a>
<h2>About Cencora</h2>
Cencora is one of three domestic leading pharmaceutical wholesalers. It sources and distributes branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospital networks, and healthcare providers. It and McKesson and Cardinal Health constitute over 90% of the us pharmaceutical wholesale industry. Cencora also provides commercialization services for manufacturers of pharmaceuticals and medical devices, global specialty drug logistics (World Courier), and animal health product distribution (MWI Animal Health). Cencora expanded its international presence in 2021 by purchasing Alliance Healthcare, one of the leading drug wholesalers in Europe.
<h3>Cencora's Financial Performance</h3>
Market Capitalization Analysis: The company's market capitalization surpasses industry averages, showcasing a dominant size relative to peers and suggesting a strong market position.
Revenue Growth: Cencora displayed positive results in 3 months. As of 30 June, 2024, the company achieved a solid revenue growth rate of approximately 10.9%. This indicates a notable increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Health Care sector.
Net Margin: Cencora's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 0.65% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 48.15%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): Cencora's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 0.74% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: With a high debt-to-equity ratio of 5.11, Cencora faces challenges in effectively managing its debt levels, indicating potential financial strain.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Deep Dive Into Cencora Stock: Analyst Perspectives (5 Ratings)

JP Morgan analyst Lisa Gill maintains Cencora (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COR#NYSE">COR</a>) with a Overweight and raises the price target from $280 to $287.

JP Morgan Maintains Overweight on Cencora, Raises Price Target to $287

Cencora's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COR#NYSE">COR</a>) short percent of float has risen 3.85% since its last report. The company recently reported that it has 8.56 million shares sold short, which is 5.93% of all regular shares that are available for trading. Based on its trading volume, it would take traders 6.62 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Cencora Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1723645811_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Cencora has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Cencora's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Cencora's peer group average for short interest as a percentage of float is 3.99%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

Peering Into Cencora's Recent Short Interest

Cencora (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COR#NYSE">COR</a>) has outperformed the market over the past 5 years by 10.17% on an annualized basis producing an average annual return of 23.42%. Currently, Cencora has a market capitalization of $46.92 billion. 
Buying $100 In COR: If an investor had bought $100 of COR stock 5 years ago, it would be worth $271.59 today based on a price of $238.13 for COR at the time of writing.
<h3>Cencora's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1722607236_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Cencora, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COR#NYSE">COR</a>) today announced that it has agreed to repurchase shares of its common stock from Walgreens Boots Alliance Holdings LLC in the amount of approximately $250 million in concurrence with Walgreens Boots Alliance's sale of Cencora shares pursuant to Rule 144 under the Securities Act of 1933, as amended.
Cencora intends to repurchase shares from Walgreens Boots Alliance at the price per share equal to the price in the Rule 144 sale. The concurrent share repurchase will be made under Cencora's share repurchase program and the repurchased shares will be held in treasury.

Buybacks

Cencora Announces $250M Common Share Repurchase From Walgreens Boots Alliance

Transaction Highlights
<ul>
<li>Walgreens Boots Alliance announces sale of all remaining unencumbered shares of Cencora, Inc. for proceeds of approximately $1.1 billion</li>
<li>$818 million sold pursuant to Rule 144 along with a concurrent share repurchase by Cencora of $250 million</li>
<li>Proceeds to Walgreens Boots Alliance will be used primarily for debt paydown and general corporate purposes</li>
<li>No change to ongoing collaboration and long-term strategic partnership</li>
</ul>
Walgreens Boots Alliance, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WBA#NASDAQ">WBA</a>) today announced that it has sold all of its remaining unencumbered shares of Cencora, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COR#NYSE">COR</a>) common stock pursuant to Rule 144 for proceeds of $818 million and, subject to the completion of the Rule 144 sale, a concurrent share repurchase by Cencora in the amount of $250 million.
Walgreens Boots Alliance's ownership of Cencora's common stock has decreased from approximately 12 percent to approximately 10 percent.
Proceeds to Walgreens Boots Alliance will be used primarily for debt paydown and general corporate purposes, as the company continues to build out a more capital-efficient health services strategy rooted in its retail pharmacy footprint.
The sale has no impact to the long-term partnership between the two companies. Walgreens Boots Alliance remains fully committed to the strategic, mutually beneficial relationship with Cencora, which has been a strong and trusted partner since 2013. Chief Operating Officer, International of Walgreens Boots Alliance, Ornella Barra, will continue to serve on Cencora's Board of Directors.

Asset Sales

Walgreens Boots Alliance Sells  All Remaining Unencumbered Shares Of Cencora For ~$1.1B Of Proceeds; Walgreens Boots Alliance's Ownership Of Cencora's Common Stock Has Decreased From  ~12% To ~10%

Wells Fargo analyst Stephen Baxter maintains Cencora (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COR#NYSE">COR</a>) with a Equal-Weight and raises the price target from $236 to $249.

Wells Fargo Maintains Equal-Weight on Cencora, Raises Price Target to $249

Baird analyst David Rodgers maintains Cencora (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COR#NYSE">COR</a>) with a Outperform and raises the price target from $285 to $287.

Baird Maintains Outperform on Cencora, Raises Price Target to $287

WIIM

Cencora shares are trading higher after the company reported better-than-expected Q3 financial results and raised its FY24 adjusted EPS guidance above estimates.

Cencora Forecasts 2024 Adjusted EPS Of $13.55-$13.65 Versus Prior Guidance Of $13.35-$13.55 And Consensus Of $13.47

Analyst Allen Lutz from Bank of America Securities maintained a Buy rating on Cencora (COR – Research Report) and increased the price target to $27...

Cencora's Resilience Amid Challenges Spurs Buy Rating and Positive Growth Outlook

In a report released today, Stephanie Davis from Barclays maintained a Buy rating on Cencora (COR – Research Report), with a price target of $263.0...

Cencora (COR) Gets a Buy from Barclays

In a report released yesterday, Steve Baxter from Wells Fargo assigned a Hold rating to Cencora (COR – Research Report), with a price target of $24...

Cencora (COR) Gets a Hold from Wells Fargo

In a report released yesterday, Steve Baxter from Wells Fargo maintained a Hold rating on Cencora (COR – Research Report), with a price target of $...

Cencora: A Balanced Future Outlook Justifies Hold Rating Amid Modest Growth Projections

IHF: Healthcare Dashboard For September

Cencora: Credentials To Die For, But Underlying Issues Make Case For 'Hold' Rating

Cencora cut to Neutral at BofA; risks to Walgreens, Cigna contracts cited

These are the mid-caps that could perform best during 'downturn' regimes – BofA

Goldman rebalances low labor cost basket amid cooling labor market

Michael Ha, an analyst from Robert W. Baird, reiterated the Buy rating on Cencora (COR – Research Report). The associated price target is $287.00. ...

Comments

Cencora

매도 수량

Cencora (NYSE:COR) 주식, 공매도 수량 보고

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌